Guided Therapeutics, Inc. – OTC:GTHP
Guided Therapeutics stock price today
Guided Therapeutics stock price monthly change
Guided Therapeutics stock price quarterly change
Guided Therapeutics stock price yearly change
Guided Therapeutics key metrics
Market Cap | 11.70M |
Enterprise value | 8.13M |
P/E | -1.93 |
EV/Sales | 353.88 |
EV/EBITDA | -1.72 |
Price/Sales | 381.58 |
Price/Book | -3.04 |
PEG ratio | -0.11 |
EPS | -0.05 |
Revenue | N/A |
EBITDA | -2.88M |
Income | -3.02M |
Revenue Q/Q | -72.72% |
Revenue Y/Y | 105% |
Profit margin | -30230.43% |
Oper. margin | -19534.78% |
Gross margin | -260.87% |
EBIT margin | -19534.78% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGuided Therapeutics stock price history
Guided Therapeutics stock forecast
Guided Therapeutics financial statements
| Jun 2023 | 44K | -1.55M | -3538.64% |
|---|---|---|---|
| Sep 2023 | 0 | -677K | |
| Dec 2023 | 32K | -386K | -1206.25% |
| Mar 2024 | 6K | -402K | -6700% |
| Jun 2023 | 2348000 | 5.66M | 241.18% |
|---|---|---|---|
| Sep 2023 | 1877000 | 5.52M | 294.46% |
| Dec 2023 | 1669000 | 5.47M | 328.04% |
| Mar 2024 | 1494000 | 5.50M | 368.54% |
| Jun 2023 | -438K | 0 | -41K |
|---|---|---|---|
| Sep 2023 | -473K | 0 | -154K |
| Dec 2023 | -336K | 0 | 196K |
| Mar 2024 | -100K | 0 | -46K |
Guided Therapeutics alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 6 |
| Apr 2024 | 6 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Guided Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Sep 2024 | 3333334 | 0 |
| Dec 2024 | 3230770 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | IMHOFF JOHN E director, 10 percent owner: | Common Stock | 1,615,385 | $0.13 | $210,000 | ||
Purchase | IMHOFF JOHN E director, 10 percent owner: | Warrants | 1,615,385 | N/A | N/A | ||
Purchase | IMHOFF JOHN E director, 10 percent owner: | Common Stock | 1,666,667 | $150,000 | $250,000,050,000 | ||
Purchase | IMHOFF JOHN E director, 10 percent owner: | Warrants | 1,666,667 | $0.12 | $200,000 | ||
Purchase | IMHOFF JOHN E director, 10 percent owner: | Common Stock | 500,899 | $150,090 | $75,179,930,910 | ||
Purchase | IMHOFF JOHN E director, 10 percent owner: | Series E Preferred Stock | 250 | $0.25 | $63 | ||
Purchase | JAMES MICHAEL C director, 10 percent owner: | Common Stock | 100,000 | $0.5 | $50,000 | ||
Purchase | JAMES MICHAEL C director, 10 percent owner: | Warrants | 200,000 | $0.58 | $115,000 | ||
Purchase | CARTWRIGHT GENE S director, officer.. | Warrants | 235,650 | $0.1 | $23,565 | ||
Sale | IMHOFF JOHN E director, 10 percent owner: | Warrants | 58,935 | $0.23 | $13,260 |
Tuesday, 10 December 2024 | ||
| Guided Therapeutics Receives Order and Full Payment From Indonesia for 4 LuViva Systems and 1,200 Disposables | businesswire.com |
-
What's the price of Guided Therapeutics stock today?
One share of Guided Therapeutics stock can currently be purchased for approximately $0.26.
-
When is Guided Therapeutics's next earnings date?
Unfortunately, Guided Therapeutics's (GTHP) next earnings date is currently unknown.
-
Does Guided Therapeutics pay dividends?
No, Guided Therapeutics does not pay dividends.
-
How much money does Guided Therapeutics make?
Guided Therapeutics has a market capitalization of 11.70M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 653.85% to 98K US dollars.
-
What is Guided Therapeutics's stock symbol?
Guided Therapeutics, Inc. is traded on the OTC under the ticker symbol "GTHP".
-
What is Guided Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical Devices industry.
-
How do i buy shares of Guided Therapeutics?
Shares of Guided Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Guided Therapeutics's key executives?
Guided Therapeutics's management team includes the following people:
- Dr. Mark L. Faupel Ph.D. Chief Operating Officer, Sec. & Director(age: 70, pay: $26,000)
- Dr. Gene S. Cartwright Ph.D. Chief Executive Officer, Pres, Acting Chief Financial Officer & Director(age: 71, pay: $12,000)
-
How many employees does Guided Therapeutics have?
As Jul 2024, Guided Therapeutics employs 4 workers, which is 33% less then previous quarter.
-
When Guided Therapeutics went public?
Guided Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 21 Nov 2018.
-
What is Guided Therapeutics's official website?
The official website for Guided Therapeutics is guidedinc.com.
-
Where are Guided Therapeutics's headquarters?
Guided Therapeutics is headquartered at 5835 Peachtree Corners East, Norcross, GA.
-
How can i contact Guided Therapeutics?
Guided Therapeutics's mailing address is 5835 Peachtree Corners East, Norcross, GA and company can be reached via phone at +7 702428723.
Guided Therapeutics company profile:
Guided Therapeutics, Inc.
guidedinc.comOTC
5
Medical Devices
Healthcare
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Norcross, GA 30092
CIK: 0000924515
ISIN: US40171F5017
CUSIP: 40171F501
